Last reviewed · How we verify

NCT05584228: SMART

Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease

Not yet recruiting NA Last updated 18 October 2022
What this trial tests

NA trial testing Azathioprine + infliximab in Crohn Disease in 150 participants. Not yet recruiting.

Timeline
1 April 2023
Primary endpoint
1 October 2027
1 October 2027

Quick facts

Lead sponsorNantes University Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment150
Start date1 April 2023
Primary completion1 October 2027
Estimated completion1 October 2027

Drugs / interventions tested

Conditions studied

Sponsor

Nantes University Hospital

Who can join

Adults 18 to 70, any sex, with Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the SMART trial is to compare a combination therapy using azathioprine and subcutaneous infliximab versus ileocecal resection in patients with symptomatic small bowel Crohn's disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Fibrostenosing Crohn’s Disease: Pathogenetic Mechanisms and New Therapeutic Horizons
    · 2024

Verify or expand the search:

Other recruiting trials for Crohn Disease

Currently open trials in the same condition.

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05584228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing